多西他赛单药治疗老年晚期非小细胞肺癌的临床观察  

Clinical Observation of Docetaxel in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

作　　者：赵晓光[1] 张艳珠[1] 宋明霞[1] 

机构地区：[1]焦作市人民医院肿瘤内科,河南焦作454002

出　　处：《肿瘤基础与临床》2012年第4期299-301,共3页journal of basic and clinical oncology

摘　　要：目的观察多西他赛单药治疗老年晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法 36例老年晚期NSCLC患者应用多西他赛75 mg·m-2治疗,21 d为1周期,治疗2～4周期后评价疗效和毒副反应。结果全组总有效率为30.6%(11/36),疾病控制率为55.6%(20/36),生活质量改善率为36.1%(13/36)。主要毒副反应为骨髓抑制及消化道反应,经对症处理后可缓解。结论多西他赛单药治疗老年晚期NSCLC疗效肯定,可明显改善患者生活质量,毒副反应可耐受。Objective To evaluate the efficacy and toxicities of docetaxel alone in the treatment of the elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods Thirty six elderly patients with advanced NSCLC received the docetaxel treatment （75 mg · m-2）, every 21 days was one cycle, the efficacy and toxicities were evaluated after 2-4 cycles. Results The overall response rate was 30.6%, the disease control rate was 55.6% （20/36）, the improvement rate of quality of life was 36.1%. The major toxicities were myelosuppression and gastrointestinal reaction, and they were catabatic after the symptomatic treatment. Conclusion Docetaxel alone is effective for the elderly patients with advanced NSCLC, it can improve the quality of life of patients, and the tox- icities can be tolerated.

关 键 词：多西他赛 非小细胞肺癌 疗效 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]